Results 41 to 50 of about 2,141 (187)

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial [PDF]

, 2021
Background: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. Objective: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib treatment, dose reduction or withdrawal ...
Gubelin, Walter, Valenzuela, Fernando, Lynde, Charles W., Blauvelt, Andrew, Criado, Paulo Ricardo, Eisman, Samantha, DiBonaventura, Marco, Cameron, Michael C., Feeney, Claire, Bieber, Thomas, Biswas, Pinaki, Simpson, Eric L., Zdybski, Jacek, Rojo, Ricardo, Silverberg, Jonathan I., Valdez, Hernan, Khan, Tahira, Valenzuela Ahumada, Fernando Alfredo, Lebwohl, Mark G.   +18 more
core   +1 more source

Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials

JEADV Clinical Practice, 2023
Background Patients with moderate‐to‐severe atopic dermatitis (AD) refractory to topical therapy might require treatment with systemic therapies, including biologics. Objectives To assess the efficacy and safety of abrocitinib monotherapy in patients who
Melinda J. Gooderham, Michael R. Ardern‐Jones, Emma Guttman‐Yassky, Mahreen Ameen, Eric L. Simpson, Gary Chan, Pinaki Biswas, Wing S. Chiu, Melissa Watkins   +8 more
doaj   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Dermatology Research and Practice, 2021
Background. Atopic dermatitis (AD) is a complex, chronic, inflammatory skin disease characterized by pruritic, intense itching, and eczematous lesions affecting about 25% of children and 2% to 3% of adults worldwide.
Hammad Ali Fadlalmola, Muayad Saud Albadrani, Amal Mohamed Elhusein, Wahieba E. Mohamedsalih, D. S. Veerabhadra Swamy, Daniel Mon Mamanao   +5 more
doaj   +1 more source

Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis

Pifu-xingbing zhenliaoxue zazhi, 2023
Atopic dermatitis (AD) is an inflammatory skin disease characterized by pruritus. The efficacy of traditional treatment for moderate and severe AD is not satisfactory.
Xu ZHU, Wenzhong WU
doaj   +1 more source

Abrocitinib for atopic dermatitis [PDF]

The Lancet, 2021
Shelley K, Uppal, Vipawee S, Chat, Donovan G, Kearns, Jashin J, Wu   +3 more
openaire   +2 more sources

4‐1BBL Suppresses Anti‐Inflammatory Responses by Regulating Metabolic Reprogramming of Macrophages

Immunology, EarlyView.
4‐1BB ligand (4‐1BBL) is known to promote sustained pro‐inflammatory responses in macrophages. This study demonstrates that 4‐1BBL acts as a negative regulator of anti‐inflammatory macrophage responses. Genetic deletion or pharmacological inhibition of 4‐1BBL significantly enhanced the phosphorylation of IL‐4R‐proximal JAK1 and STAT6, elevating the ...
Young Jun Kang
wiley   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source